Therapeutic Potential of Ellagic Acid in Liver Diseases
Open Access
Abstract
Ellagic acid (EA) is a natural polyphenol found in various fruits, nuts, and mushrooms. It exhibits a variety of biological activities, including potent antioxidant, anti-inflammatory, anti-obesity, and neuroprotective properties. EA exerts hepatoprotective effects through multiple mechanisms, including (1) scavenging reactive oxygen species (ROS) and enhancing endogenous antioxidant defenses (e.g., by activating Nrf2/ARE), (2) modulating inflammatory signaling pathways (e.g., inhibiting NF-κB, TNF-α, and IL-6), and (3) regulating apoptosis (e.g., downregulating the Bax/Bcl-2 ratio) and fibrosis (e.g., inhibiting TGF-β/Smad signaling). Despite its promising preclinical efficacy, the clinical applicability of EA is currently limited by its poor bioavailability. This could potentially be overcome by advanced delivery systems or by directly administering its active microbial metabolites, known as urolithins. EA and its derivatives also modulate the gut microbiota, promoting the growth of beneficial species and reducing gut permeability and hepatic inflammation. Preliminary clinical trials and other emerging evidence suggest that EA may reduce liver inflammation, oxidative stress, and metabolic dysregulation. However, more extensive human studies are needed to confirm its efficacy and safety in managing liver disease. This review highlights the therapeutic potential of EA in the treatment of liver diseases, particularly metabolic-dysfunction-associated steatotic liver disease (MASLD).Keywords
Funding Information
- Medical University of Lublin (DS 12)
This publication has 139 references indexed in Scilit:
- Pomegranate‐Derived Exosome‐Like Nanovesicles Containing Ellagic Acid Alleviate Gut Leakage and Liver Injury in MASLDFood Science & Nutrition, 2025
- Ellagic Acid and Gut Microbiota: Interactions, and Implications for HealthFood Science & Nutrition, 2025
- Randomized double‐blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetesPhytotherapy Research, 2020
- Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a DecadeHepatology, 2020
- Antiinflammatory and anti‐cancer activities of pomegranate and its constituent, ellagic acid: Evidence from cellular, animal, and clinical studiesPhytotherapy Research, 2020
- Investigation of the profile of phenolic compounds in the leaves and stems of Pandiaka heudelotii using gas chromatography coupled with flame ionization detectorFood Science & Nutrition, 2016
- Pomegranate juice prevents development of non‐alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammationJournal of the Science of Food and Agriculture, 2016
- An aqueous pomegranate seed extract ameliorates oxidative stress of human hepatoma HepG2 cellsJournal of the Science of Food and Agriculture, 2013
- The quantification of ellagic acid in the crude extract of Phyllanthus amarus Schum. & Thonn. (Euphorbiaceae)Phytochemical Analysis, 2010
- Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trialsInternational Journal of Cancer, 2008